Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;46(7):880-890.
doi: 10.1007/s00270-023-03446-6. Epub 2023 Jun 19.

Prospective Series of Transarterial Chemoembolization of Metastatic Colorectal Cancer to the Liver with 30-60 μm Microspheres Loaded with Irinotecan

K Malagari  1   2 , Th Kiakidis  3   4 , H Moschouris  5 , A Charokopakis  3   4 , C Vergadis  6 , N Alevisopoulos  7 , V Kartsouni  8 , Ir Panagiotou  9 , O Pellerin  10 , G Glantzounis  11 , D K Filippiadis  3   4 , E Emmanouil  12 , N Tsavaris  13 , G Psarros  14 , E Delicha  14 , N Kelekis  3   4
Affiliations

Prospective Series of Transarterial Chemoembolization of Metastatic Colorectal Cancer to the Liver with 30-60 μm Microspheres Loaded with Irinotecan

K Malagari et al. Cardiovasc Intervent Radiol. 2023 Jul.

Abstract

Purpose: To describe safety and clinical outcomes among patients with metastatic colorectal cancer (mCRC) to the liver treated with transarterial chemoembolization with HepaSphere™ Microspheres 30-60 μm loaded with irinotecan (ΙRI-HEP-TACE).

Material and methods: In this prospective study (NCT04866290), 100 adults with confirmed mCRC to the liver who were ineligible for resection were enrolled and followed up to 24 months or death. Study outcomes among Salvage (patients not tolerating more cycles of chemotherapy) and Non-salvage patients included overall survival (OS), progression-free survival (PFS), objective response (OR), objective response rate (ORR), best tumor response (BTR), adverse events (AEs), and pharmacokinetics of irinotecan and its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN38).

Results: The median age was 66 years (range: 31-89). Median OS was 15.08 months (95% confidence interval [CI]: 12.33-17.25). PFS was 8.52 months (95% CI: 6.0-9.0; p < 0.001). ORR was 42.2% (95% CI: 31.57-53.50) and 35.9% (95% CI: 25.57-47.62) based on modified RECIST (Response Evaluation Criteria in Solid Tumors) and RECIST 1.1 criteria. BTR was not significantly different between mRECIST and RECIST (p = 0.745). The Non-salvage group had a statistically significant difference in median OS relative to the Salvage group (15.3 vs. 3 months; p < 0.001). Pharmacokinetic analyses demonstrated no correlation of OS with plasma concentration of irinotecan and SN38 (all p > 0.05). Most AEs were Grade 2 (257/279), the most common AE was right upper abdominal pain (180/279). One major AE (tumor rupture) was reported.

Conclusion: IRI-HEP-TACE is an alternative treatment for patients with Non-salvage mCRC to the liver.

Keywords: Drug-eluting microspheres; HepaSphere™ microspheres 30–60 μm; Irinotecan; Liver metastatic colorectal cancer (mCRC).

PubMed Disclaimer

References

    1. Lewis AL, Hall B. Toward a better understanding of the mechanism of action for intra-arterial delivery of irinotecan from DC Bead((TM)) (DEBIRI). Future Oncol. 2019;15(17):2053–68. - PubMed - DOI
    1. Akinwande O, Scoggins C, Martin RC. Early Experience with 70–150 μm irinotecan drug-eluting beads (M1-DEBIRI) for the treatment of unresectable hepatic colorectal metastases. Anticancer Res. 2016;36(7):3413–8. - PubMed
    1. Liu DM, Thakor AS, Baerlocher M, Alshammari MT, Lim H, Kos S, et al. A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof. Future Oncol. 2015;11(9):1421–8. - PubMed - DOI
    1. Young S, D’Souza D, Flanagan S, Golzarian J. Review of the clinical evidence for the use of DEBIRI in the treatment of colorectal metastatic disease. Cardiovasc Intervent Radiol. 2017;40(4):496–501. - PubMed - DOI
    1. Huppert P, Wenzel T, Wietholtz H. Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. Cardiovasc Intervent Radiol. 2014;37(1):154–64. - PubMed - DOI

Publication types

LinkOut - more resources